{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:59:28Z","timestamp":1785283168657,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jdcr.2026.01.027","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:54:33Z","timestamp":1769705673000},"page":"55-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pembrolizumab-induced oral erosive lichen planus treated with dupilumab"],"prefix":"10.1016","volume":"70","author":[{"given":"Lisa S.","family":"Mun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndidi","family":"Enwereji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6951-2894","authenticated-orcid":false,"given":"Steven","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jdcr.2026.01.027_bib1","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jdcr.2026.01.027_bib2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jdcr.2026.01.027_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2026.01.027_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.jdcr.2026.01.027_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.jdcr.2026.01.027_bib6","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/ijd.17850","article-title":"Dupilumab for the treatment of cutaneous immune-related adverse events: a systematic review","volume":"64","author":"Koumprentziotis","year":"2025","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jdcr.2026.01.027_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"issue":"5","key":"10.1016\/j.jdcr.2026.01.027_bib8","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.oooo.2020.06.014","article-title":"Severe oral erosive lichenoid reaction to pembrolizumab therapy","volume":"130","author":"Bhattacharyya","year":"2020","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"3","key":"10.1016\/j.jdcr.2026.01.027_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/JD9.0000000000000335","article-title":"Pembrolizumab-induced erosive lichenoid reaction in a patient with metastatic lung adenocarcinoma: a case report","volume":"8","author":"Venturi","year":"2025","journal-title":"Int J Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2026.01.027_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2023.05.004","article-title":"Pembrolizumab-Induced lichenoid dermatitis treated with dupilumab","volume":"37","author":"Park","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2026.01.027_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdcr.2023.05.036","article-title":"Nivolumab-Induced lichen planus responsive to dupilumab treatment in a patient with stage III C melanoma","volume":"38","author":"Zemlok","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jdcr.2026.01.027_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000527918","article-title":"Dupilumab-Induced lichen planus: a case with oral and cutaneous eruptions","volume":"14","author":"Kern","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jdcr.2026.01.027_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2022.12.013","article-title":"Lichenoid-Granulomatous drug reactions to dupilumab: a report of 2 cases","volume":"33","author":"Rehan","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jdcr.2026.01.027_bib14","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.3390\/ijms24033038","article-title":"Comprehensive insight into lichen planus immunopathogenesis","volume":"24","author":"Vi\u010di\u0107","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:27:05Z","timestamp":1785281225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"alternative-id":["S2352512626000457"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.01.027","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-induced oral erosive lichen planus treated with dupilumab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}